Drug Information

Drug (ID: DG00323) and It's Reported Resistant Information

• Name: Ormaplatin
• Synonyms: TCDCP; Tetraplatin; Tetraplatinum; U-77233
• Indication:
  In total 1 Indication(s)
  Leukaemia [ICD-11: 2A60-2B33]; Discontinued in Phase 1; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Ovarian cancer [ICD-11: 2C73]; [1]
• Formula: C6H14Cl4N2Pt
• IsoSMILES: C1CCC(C(C1)N)N.Cl[Pt](Cl)(Cl)Cl
• InChI: 1S/C6H14N2.4ClH.Pt/c7-5-3-1-2-4-6(5)8;;;;;/h5-6H,1-4,7-8H2;4*1H;/q;;;;;+4/p-4
• InChIKey: VPOCYEOOFRNHNL-UHFFFAOYSA-J
• PubChem CID: 13920603
• TTD Drug ID: D00HMQ

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ovarian cancer [ICD-11: 2C73]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Cancer susceptibility 11 (CASC11) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Ovarian squamous cell carcinoma [ICD-11: 2C73.3]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: UWB1.289 cells; Ovary; Homo sapiens (Human); CVCL_B079
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy (oxaliplatin, tetraplatin, cisplatin, and carboplatin).

References

• Ref 1: Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy. Gene. 2019 Aug 20;710:363-366. doi: 10.1016/j.gene.2019.06.011. Epub 2019 Jun 7.